VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology and increased genetic testing are key drivers for market growth. However, competition from other…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.